Celcuity Inc. (CELC) Drops 0.31% After Earnings

2026-05-15 · Stocks · QuoteReporter

Post Earning Analysis

Celcuity Inc. (CELC) Drops 0.31% After Earnings

Celcuity Inc., founded in January 2012 and based in Minneapolis, MN, is a cellular analysis company focused on the discovery of new cancer sub-types and the commercialization of diagnostic tests. These tests are designed to enhance the treatment outcomes of cancer patients using targeted therapies. Their proprietary CELx diagnostic platform uses living tumor cells to pinpoint abnormal cellular processes driving a patient’s cancer and identifies suitable targeted therapies.

Celcuity Inc. (NASDAQ: CELC) has recently shared several significant updates that could impact its stock. On May 15, 2026, during their Q1 earnings call, the company highlighted promising developments in clinical trials and strategic advancements, suggesting potential future growth in their pipeline. Additionally, on May 14, 2026, Celcuity reported the release of their first quarter financial results for 2026 along with a corporate update, indicating a transparent and regular communication strategy with investors which is generally viewed positively by the market.

Furthermore, Celcuity announced an expansion in their Phase 3 VIKTORIA-2 trial of Gedatolisib, aimed at treating HR+/HER2- advanced breast cancer. This trial will now also include endocrine-sensitive patients, broadening the potential applicability and market of the drug. This expansion could significantly enhance the drug's commercial profile and market reach upon successful trial outcomes and eventual FDA approval.

These developments could potentially boost investor confidence and positively influence Celcuity's stock, given the expanded scope of their flagship clinical trial and clear communication of their financial health and strategic direction.

The current price of the asset is $134.79, which marks a slight decrease of 0.31% today. This price is significantly above both the 52-week and year-to-date lows ($9.51 and $7.57, respectively), indicating a robust upward trend throughout the year. The price is currently down 10.75% from the 52-week and YTD highs of $151.02, suggesting a recent pullback or correction.

The asset has surpassed all its moving averages (20-day, 50-day, and 200-day) by 5.84%, 12.65%, and 49.04%, respectively, highlighting strong bullish momentum over these periods. This is further supported by a Relative Strength Index (RSI) of 58.08, which is near the upper end of the neutral range, leaning towards overbought territory but not excessively so.

The Moving Average Convergence Divergence (MACD) of 3.62 indicates positive momentum as the MACD line is above the signal line, reinforcing the overall bullish trend. However, the recent price is 3.46% below the week's high, indicating some short-term volatility or potential resistance near the $139.62 level.

Overall, the asset shows strong long-term gains with recent short-term pullbacks, suggesting potential buying opportunities if the bullish trend continues.

The most recent rating changes for the stock in question present a positive trajectory in terms of both analyst sentiment and target price adjustments.

Overall, these ratings indicate a growing optimism among analysts regarding the stock's future performance, with a clear upward trend in target prices over a short period. This pattern suggests increasing confidence in the company's prospects, potentially driven by fundamental improvements in its operations or market conditions.

The current price of the stock is $134.79, which is situated above the average target price set by Wolfe Research at $110 and Wells Fargo at $126, but below the more optimistic targets set by Citizens and H.C. Wainwright at $150 and $165, respectively. These target prices suggest a mixed but generally positive outlook from analysts, with recent upgrades indicating a growing optimism about the stock’s performance.

The variation in target prices and recent upgrades to "Buy" from H.C. Wainwright, as well as the initiation of coverage with favorable ratings such as "Market Outperform" and "Overweight" from Citizens and Wells Fargo, respectively, imply a potential for growth and a bullish sentiment among analysts. This could be reflective of improving fundamentals, possibly indicated by recent earnings per share (EPS) trends and dividend policies, although specific EPS figures and dividend data have not been detailed in the provided information. Overall, the stock appears to be favorably viewed by analysts with expectations of upward movement in its valuation.

Disclaimer: The information provided here is for educational and informational purposes only and should not be interpreted as financial advice, investment recommendations, or trading guidance. Markets involve risk, and past performance is not indicative of future results. You should always conduct your own research and consult with a qualified financial advisor before making any investment decisions. By acting, you accept full responsibility for your choices.